2 results
Approved WMOCompleted
Primary:To evaluate the effects of 15 mg E4/3 mg DRSP, of 30 mcg EE/150 mcg LNG, and of 20 mcg EE/3 mg DRSP on hemostasis, endocrine function and lipid and carbohydrate metabolism parameters during 6 treatment cycles.Secondary:To assess the safety…
Approved WMOPending
Primary Objective:To validate the ExSpiron©, a device for non-invasive monitoring of respiratory volume in patients with ALS during spontaneous breathing and during NIV.Secondary Objective(s):• to observe the difference between nocturnal respiration…